GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantabio Pharmaceuticals Inc (OTCPK:CTBO) » Definitions » 6-Month Share Buyback Ratio

CTBO (Cantabio Pharmaceuticals) 6-Month Share Buyback Ratio : 0.00% (As of Dec. 2018 )


View and export this data going back to 2013. Start your Free Trial

What is Cantabio Pharmaceuticals 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Cantabio Pharmaceuticals's current 6-Month Share Buyback Ratio was 0.00%.

Competitive Comparison of Cantabio Pharmaceuticals's 6-Month Share Buyback Ratio

For the Biotechnology subindustry, Cantabio Pharmaceuticals's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantabio Pharmaceuticals's 6-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantabio Pharmaceuticals's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Cantabio Pharmaceuticals's 6-Month Share Buyback Ratio falls into.


;
;

Cantabio Pharmaceuticals 6-Month Share Buyback Ratio Calculation

Cantabio Pharmaceuticals's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2018 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Jun. 2018 ) - Shares Outstanding (EOP) (Dec. 2018 )) / Shares Outstanding (EOP) (Jun. 2018 )
=(0.011 - 0.019) / 0.011
=-72.73%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals  (OTCPK:CTBO) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Cantabio Pharmaceuticals 6-Month Share Buyback Ratio Related Terms

Cantabio Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantabio Pharmaceuticals Inc (OTCPK:CTBO) » Definitions » 6-Month Share Buyback Ratio
Comparable Companies
OSTO:BAYN WAR:SCS TNTY WAR:PFM ETNI NTRR ADYNF XSAT:NORI TSXV:PBS PPCB LSE:PEBI CBBT OBMP BPSR PTEO TSXV:ICO TSXV:IOT TSXV:WAVE SOAN FNAM
Traded in Other Exchanges
N/A
Address
1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Website
http://www.cantabio.com
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.